Long-Term Omalizumab Treatment: A Multicenter, Real-Life, 5-Year Trial

Simple item page
dc.contributor.authorYorgancloǧlu A.
dc.contributor.authorErkekol F.Ö.
dc.contributor.authorMungan D.
dc.contributor.authorErdinç M.
dc.contributor.authorGemicioǧlu B.
dc.contributor.authorÖzşeker Z.F.
dc.contributor.authorBayrak Deǧirmenci P.
dc.contributor.authorNaycl S.
dc.contributor.authorÇilli A.
dc.contributor.authorErdenen F.
dc.contributor.authorKlrmaz C.
dc.contributor.authorEdiger D.
dc.contributor.authorYalçln A.D.
dc.contributor.authorBüyüköztürk S.
dc.contributor.authorÖztürk S.
dc.contributor.authorGüleç M.
dc.contributor.authorIşlk S.R.
dc.contributor.authorKalyoncu A.F.
dc.contributor.authorGöksel Ö.
dc.contributor.authorAydln Ö.
dc.contributor.authorHavlucu Y.
dc.contributor.authorBaloǧlu Ar I.
dc.contributor.authorErdoǧdu A.
dc.date.accessioned2024-07-22T08:09:42Z
dc.date.available2024-07-22T08:09:42Z
dc.date.issued2018
dc.description.abstractBackground: Omalizumab has demonstrated therapeutic benefits both in controlled clinical trials and real-life studies. However, research concerning the long-term effects and tolerability of omalizumab is needed. The main objective of this study was to evaluate the effectiveness and tolerability of treatment with omalizumab for up to 5 years. Methods: A multicenter, retrospective, chart-based study was carried out to compare documented exacerbations, hospitalizations, systemic steroid requirement, FEV1, and asthma control test (ACT) results during 1 year prior to omalizumab treatment versus at 1, 3, and 5 years of treatment. Adverse events and reasons for discontinuation were also recorded at each time point. Results: Four hundred and sixty-five patients were enrolled in the study. Outcome variables had improved after the 1st year and were sustained after the 3rd and 5th years of treatment with omalizumab. Omalizumab treatment reduced the asthma exacerbation rate by 71.3% (p < 0.001) at 1 year, 64.3% (p < 0.001) at 3 years, and 54.8% (p = 0.002) at 5 years. The hospitalization rate also decreased; by the 5th year of the treatment no patients were hospitalized. ACT results had also improved significantly: 12 (p < 0.001) at 1 year, 12 (p < 0.001) at 3 years, and 12 (p = 0.002) at 5 years. Overall, 12.7% of patients reported adverse events (most of these were mild-to-moderate) and the overall dropout rate was 9.0%. Conclusion: Omalizumab had a significant effect on asthma outcomes and this effect was maintained over 5 years. The drug was found to be generally safe and treatment compliance was good. © 2018 S. Karger AG, Basel. Copyright: All rights reserved.
dc.identifier.DOI-ID10.1159/000488349
dc.identifier.issn10182438
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/14935
dc.language.isoEnglish
dc.publisherS. Karger AG
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectAnti-Asthmatic Agents
dc.subjectAsthma
dc.subjectFemale
dc.subjectForced Expiratory Volume
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectOmalizumab
dc.subjectRetrospective Studies
dc.subjectYoung Adult
dc.subjectbeta 2 adrenergic receptor stimulating agent
dc.subjectcorticosteroid
dc.subjectleukotriene receptor blocking agent
dc.subjectneuroleptic agent
dc.subjectomalizumab
dc.subjectantiasthmatic agent
dc.subjectomalizumab
dc.subjectadult
dc.subjectaged
dc.subjectallergic asthma
dc.subjectArticle
dc.subjectAsthma Control Test
dc.subjectchronopharmacology
dc.subjectclinical decision making
dc.subjectclinical evaluation
dc.subjectclinical outcome
dc.subjectcomparative study
dc.subjectcorticosteroid therapy
dc.subjectdisease exacerbation
dc.subjectdrug efficacy
dc.subjectdrug safety
dc.subjectdrug tolerability
dc.subjectdrug withdrawal
dc.subjectfemale
dc.subjectforced expiratory volume
dc.subjecthospital patient
dc.subjecthospitalization
dc.subjecthuman
dc.subjectlong term care
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmedical documentation
dc.subjectmedical record review
dc.subjectmedication compliance
dc.subjectmyopathy
dc.subjectoutcome variable
dc.subjectpatient compliance
dc.subjectpatient dropout
dc.subjectpersonal experience
dc.subjectpneumonia
dc.subjectpregnancy
dc.subjectpriority journal
dc.subjectprostate carcinoma
dc.subjectretrospective study
dc.subjectself report
dc.subjectside effect
dc.subjectsystemic therapy
dc.subjecttraffic accident
dc.subjecttreatment duration
dc.subjecttreatment refusal
dc.subjectadolescent
dc.subjectasthma
dc.subjectclinical trial
dc.subjectmiddle aged
dc.subjectmulticenter study
dc.subjectpathophysiology
dc.subjectvery elderly
dc.subjectyoung adult
dc.titleLong-Term Omalizumab Treatment: A Multicenter, Real-Life, 5-Year Trial
dc.typeArticle

Files

Collections

Scopus Koleksiyonu